Successful explantation of a corneal microlens for presbyopia and implantation of a trifocal IOL in a patient who developed ...

Researchers at the University of Granada have developed corneal implants from fish scales with promising results in the laboratory and in animals. The finding opens a way to reduce dependence on ...

Background Ocular chronic graft versus host disease (oGVHD) seriously affects ocular surface, which often results in corneal epithelial damage. The purpose of this study is to evaluate corneal ...

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...

Recurrent corneal erosions (RCE) is a common condition in which the patient typically suffers from episodes of sudden eye pain, usually upon first awakening, accompanied by redness, photophobia, and ...

Bacteria live throughout the human body. The eye was long thought to be an exception. Dr. Anthony St. Leger, a professor of ophthalmology and immunology at the University of Pittsburgh, shattered that ...

Serious diseases affecting the transparent part of the eye, called the cornea, are very difficult to treat because this ...

Int Ophthalmol Clin. 2013;53(4):1-10. Delayed presentation of corneal trauma or severe injuries may result in corneal perforation and loss of corneal tissue. These injuries are more difficult to close ...

OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye ...

Faridabad: Corneal blindness is the second leading cause of blindness in India with a current burden of 1.1 million people. The incidence rate of corneal blindness in India has seen an increase in ...

Analysts from Lucid Capital, H.C. Wainwright, and B. Riley Securities have all repeated ‘Buy’ ratings on OKYO Pharma Ltd ...